Healthcare diagnostics firm Molbio achieved unicorn status after a $85 million funding round led by Temasek in September 2022, but its success was short-lived, lasting only through the pandemic. Molbio’s revenue plummeted 74%, from Rs 1,272 crore in FY21 to Rs 332 crore in FY23. Significantly, the company slipped into losses in FY23 and posted …
Continue reading "After Rs 215 Cr profit in FY22, Molbio reports Rs 3 Cr loss in FY23"
The post After Rs 215 Cr profit in FY22, Molbio reports Rs 3 Cr loss in FY23 appeared first on Entrackr.